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OBJECTIVE—Upper body fat is associated with increased cardiometabolic risk. More re-
cently, neck circumference (NC) and/or neck fat have been associated with hyperlipidemia,
impaired glucose homeostasis, and hypertension. The objective of this study was to determine
whether this relationship is evident in HIV-infected individuals, who often exhibit changes in
relative fat distribution, and to determine whether NC is independently associated with carotid
intima-media thickness (cIMT) in HIV and non–HIV-infected patients.
RESEARCH DESIGN AND METHODS—Body composition, including anthropometrics,
visceral adipose tissue assessment by CT, and metabolic parameters, including lipids, cIMT, and
oralglucosetolerancetest,weremeasuredin174menandwomenwithHIVinfectionand154non–
HIV-infected subjects. NC was measured in triplicate inferior to the laryngeal prominence.
RESULTS—In univariate analysis, NC was signiﬁcantly and positively related to blood pres-
sure, hemoglobin A1c, glucose, and insulin and signiﬁcantly and negatively related to HDL
cholesterol in HIV-infected individuals and HIV-negative control subjects. NC was signiﬁcantly
associated with cIMT in univariate regression analysis among HIV-infected (r =0 . 2 1 ,P =0 . 0 0 6 )
and non–HIV-infected (r =0 . 3 1 ,P = 0.0001) patients. This relationship remained signiﬁcant
among non–HIV-infected patients (R
2 = 0.45, P , 0.001) but not HIV-infected patients in
multivariate modeling controlling for age, sex, race, smoking hypertension, glucose, and lipids.
CONCLUSIONS—A m o n gb o t hH I Va n dn o n –HIV-infected patients, increased NC is
strongly associated with decreased HDL and impaired glucose homeostasis. Among non–HIV-
infected subjects, NC also predicts increased cIMT when controlling for traditional risk factors.
Diabetes Care 34:1026–1031, 2011
C
ardiovascular disease (CVD) is a
leadingcauseofmorbidityandmor-
tality in the U.S.. In HIV disease,
CVDismoreprevalentthaninthegeneral
population (1). Adiposity is a well known
risk factor for cardiovascular morbidity,
and recent research highlights the cardio-
vascular risk conferred by speciﬁcp a t -
terns of fat distribution, particularly
visceral and upper body adiposity (2,3).
The role of body fat distribution is of par-
ticular importance in HIV infection, be-
cause over half of infected individuals
experience peripheral fat atrophy and/or
increased central adiposity. Body fat re-
distribution may be related to HIV itself
but is more commonly related to antire-
troviral (ARV) medications, traditional
CVD risk factors, andpoorlifestyle habits
(4,5). The cardiometabolic risk conferred
by increased visceral fat in HIV infection
has been well characterized (6,7). Upper
trunk fat has also been identiﬁed as a
strong determinant of insulin resistance
in this population (8); however, neck
circumference (NC) has not been investi-
gated. In the non–HIV-infected popula-
tion, a recent study looking at NC
concluded that NC is associated with
CVD risk factors even after adjustment
for visceral adipose tissue (VAT) and
BMI (9). In the current study, we sought
to examine NC among HIV-infected and
non–HIV-infectedmenandwomentode-
termine whether NC independently re-
lates to cardiometabolic risk controlling
for BMI and more sophisticated measure-
ments of adiposity. Furthermore, we
sought for the ﬁrst time to investigate
the association of NC to subclinical ath-
erosclerosis as measured by carotid
intima-media thickness (cIMT).
RESEARCH DESIGN AND
METHODS—Data were collected from
2000 to 2007 in 174 HIV-infected sub-
jects at the Massachusetts General Hos-
pital (MGH) and the Massachusetts
Institute of Technology (MIT), and 154
HIV-negative subjects simultaneously
were recruited from the community as
control subjects. The subjects in this
study comprise a convenience cohort for
the purposes of the current analysis,
consisting of baseline data collected for
two observational studies, in which NC
and cIMT data were available in HIV-
infected and BMI, age, and race-matched
non–HIV-infected control subjects re-
cruited based on similar criteria. The ﬁrst
cohort recruited consisted of HIV-infected
women and female control subjects,
whereas the second cohort consisted of
HIV and non–HIV-infected men and
women. For each study, consecutive
HIV-infected subjects between 18 and 65
years of age were enrolled without regard
to fat distribution. Subjects in both the
HIV and non-HIV groups were excluded
if they had a known history of diabetes;
were receiving insulin, antidiabetic agents,
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ORIGINAL ARTICLEglucocorticoids, growth hormone, supra-
physiologic testosterone replacement, or
anabolic steroids; or were pregnant or
breastfeeding within the past year. Partial
data on 199 patients were published pre-
viously(10)butdidnotincludeananalysis
of NC. All participants provided informed
consent. The studies were approved by the
Institutional Review Boards at both the
MGH and MIT.
Body composition
Weight and anthropometric measure-
ments were determined before breakfast.
All measurements were obtained using a
nonelastic tape; measurements were ob-
tainedintriplicate andthenaveraged. NC
was obtained with the subject sitting with
head in the Frankfort Horizontal Plane
position. A measuring tape was applied
around the neck inferior to the laryngeal
prominence and perpendicular to the
long axis of the neck, and the minimal
circumference was measured and recor-
ded to the nearest 0.1 cm. Intrasubject
variability in the NC measurement was
examined, and the difference between
maximal and minimal measures averaged
0 . 3 % .W a i s t ,h i p ,a r m ,a n dc h e s tc i r c u m -
ferences were determined. To assess ab-
dominalvisceralandsubcutaneousadipose
tissue area (VAT and SAT, respectively), a
cross-sectional abdominal CT scan at the
level of the L4 pedicle was performed (11).
Dual X-ray absorptiometry to assess body
fat composition was performed using a
Hologic densitometer (Hologic, Waltham,
MA).Inoneofthecohorts,physicalactivity
was assessed using the Modiﬁable Activity
Questionnaire (12).
cIMT
Imaging was conducted using a 7.5-MHz
phased–array transducer (SONOS 2000/
2500; Hewlett-Packard, Andover, MA) as
described previously (13). The published
reproducibility of the technique is excel-
lent with a SD of 0.007 mm (13). The
cIMT over the length of the left and right
segments was averaged. Although there
were no statistical differences between
left and right cIMT measurements, with
a good univariate correlation between the
two sides (r = 0.65, P , 0.001), there was
someintraindividualvariabilityofleftand
right cIMT measurements because of the
focal nature of atherosclerosis. Average
cIMT was used to reduce variability of
this measurement, as reported in prior
studies, such as the Atherosclerosis Risk
in Communities Study (ARIC) cohort
(14). To determine whether increasing
neck size affected the variability of the
cIMT measurement, we assessed the var-
iance of cIMT across quartiles of NC. The
SEMforthe lowest quartilewas 0.014,and
theSEMforthehighestquartilewas0.014,
suggesting minimal change in variance in
our cIMT data with increasing NC.
Biochemical indexes
Fasting insulin, glucose, triglycerides,
cholesterol, HDL cholesterol, LDL cho-
lesterol, and CD4 were measured using
standard techniques. HIV testing was per-
formedbychemiluminometricimmunoas-
say and conﬁrmed by Western blot. HIV
viral load was measured using ultrasensi-
tive assay.
A 75-g oral glucose tolerance test
(OGTT) was performed after a 12-h over-
night fast.
Statistical analysis
Comparison of demographic variables
was made using Student t test for contin-
uousvariablesand thex
2 test for noncon-
tinuous variables. Pearson correlation
coefﬁcients were assessed in univariate
analysis. Multivariate regression analysis
using standard least squares was per-
formed. All multivariate analyses con-
trolled for age, sex, race, and HIV status.
Cumulative exposure to ARVs by class,
e.g., nucleoside reverse transcriptase in-
hibitor (NRTI), was used when examin-
ing the effect of ARVs. In multivariate
modeling for cIMT, there was not an in-
teraction between NC and HIV status,
permitting use of a combined model.
For clinical relevance, we also provided
separate models of the relationship be-
tween NC and cIMT. The study was able
to detect an approximate 9-mm change in
cIMT for each 1-cm change in NC, with
power of 0.8 in the HIV and non-HIV
groups. All analyses were performed us-
ing SAS JMP (SAS Institute, Cary, NC).
Results are means 6 SEM.
RESULTS
Demographic data
HIV-infected and control subjects were
s i m i l a ri na g ea n ds e x(Table 1).T h e r e
was no difference in racial composition
of the groups (HIV, 36% Caucasian,
43% black, 16% Hispanic, 5% other;
non-HIV, 38% Caucasian, 47% black,
10% Hispanic, 5% other; P = 0.18). The
HIV group had a signiﬁcantly higher per-
centage of current smokers (52 versus
26%) and previous smokers (16 versus
12%) and a higher number of lifetime
pack-years(Table1).Althoughknowndi-
abeteswasanexclusioncriterionforentry
into the study, a small percentage of sub-
jects had a fasting glucose or 2-h glucose
in diabetic range (Table 1).
Among the HIV-infected group, 84%
of HIV-infected subjects were currently
being treated with combination ARV
therapy: 45% currently on protease in-
hibitors (PIs), 82% on NRTIs, and 25%
on non-nucleoside reverse transcriptase
inhibitors (NNRTIs). See Table 1 for du-
ration of use of each class of antiretroviral
therapy.
Metabolic parameters
Two-hour glucose, fasting insulin, and
triglycerides were all signiﬁcantly higher
among HIV-infected subjects compared
with control subjects. In contrast, HDL
cholesterolwassigniﬁcantlyloweramong
HIV-infected subjects. These differences
persisted when controlling for sex (see
adjusted P value; Table 1).
Anthropometric measurements
Waist-to-hip ratio (WHR) and VAT were
signiﬁcantly higher among HIV-infected
subjects, whereas SAT and arm circum-
ference were signiﬁcantly lower among
HIV-infected subjects. These differences
persisted whencontrolling for sex between
the groups (Table 1). NC was similar be-
tween groups and was not signiﬁcantly af-
fected by HIV status when controlling for
age,race, andsex(P = 0.67forHIVstatus).
By design, BMI was not different between
the two groups (Table 1).
Univariate regression analysis
relating cardiometabolic
parameters to NC
In univariate regression analysis among
all subjects, NC was signiﬁcantly related
to numerous body composition measures
and metabolic parameters (Table 2). In a
subset for which exercise data were avail-
able (n = 199), physical activity was not
related to NC (P =0 . 3 8 ) .I nt h eH I V
group,withtheexceptionoftriglycerides,
NC was related to the same parameters
as the entire cohort. Among non–HIV-
infected subjects, NC was also related to
the same parameters as in the entire co-
hort. Duration of HIV infection (r = 0.16,
P = 0.03) and cumulative exposure to
NRTIs (r =0 . 1 5 ,P =0 . 0 5 )d i ds h o wa n
a s s o c i a t i o nw i t hN Ci nu n i v a r i a t ea n a l y s i s ,
butneitherwassigniﬁcantwhencontrolling
for age. NC was not signiﬁcantly associated
with cumulative exposure to PIs (P =0 . 2 5 )
or NNRTIs (P = 0.10). CD4 count was not
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iate analysis (P =0 . 1 7 ) .H I Vv i r a ll o a dw a s
also not associated with NC (P = 0.89).
Univariate regression analysis
relating cardiometabolic
parameters to cIMT
In univariate regression analysis among
allsubjects,cIMTwassigniﬁcantlyrelated
toage,BP,hemoglobinA1c,fastingglucose,
w a i s tc i r c u m f e r e n c e ,W H R ,B M I ,V A T ,
smoking pack-years, and NC. It is note-
worthythatdual-energyX-rayabsorptiom-
etry (DEXA) measurements of upper arm
fat and trunk fat were not signiﬁcantly
associated with cIMT, in contrast with
the highly signiﬁcant relationship seen
between NC and cIMT in all groups.
Subgroup analysis among HIV and HIV-
negative subjects is shown in Table 3.
Multivariate analysis of NC in
relationship to lipid and
glucose parameters
In multivariate modeling among the en-
tire cohort, controlling for age, sex, race,
HIV status, and VAT, NC was no longer a
signiﬁcant predictor of BP, LDL, or tri-
glyceride (datanotshown).However, NC
remained a strong independent predictor
of HDL (P = 0.001), glucose (P = 0.02),
and insulin (P = 0.0002). There was no
relationship between NC and 2-h glucose
(Supplementary Table 1). When BMI was
used in the model instead of VAT, results
were similar (Supplementary Table 2). In
subanalyses, multivariate modeling was
performedseparatelyfortheHIV-infected
and HIV-negative groups (Supplementary
Tables 1 and 2). For the HIV-negative co-
hort, NC remained a signiﬁcant predictor
of HDL but did not signiﬁcantly predict
glucose or insulin. In the HIV-infected
group,NCremainedasigniﬁcantindepen-
dent predictor of HDL (P = 0.02) and fast-
ing insulin (P = 0.002). When cumulative
exposure to PI, NRTI, and NNRTI was
added to the models, results were similar.
Multivariate analysis of NC in
relationship to cIMT
Among the entire group of subjects, NC
was also a signiﬁcant predictor of average
cIMT in multivariate modeling control-
ling for HIV status and traditional cardio-
vascular risk factors, including age, sex,
race, pack-years of smoking, hyperten-
sion or use of antihypertensive medica-
tions, glucose, and LDL (P =0 . 0 2f o rN C ;
formodel,R
2=0.41 ,P,0.0001,Table4).
In this model, each 1-cm increase in NC
was associated with a 5-mm increase in
cIMT. This association remained signiﬁ-
cant when additionally controlling for
VAT (P = 0.001 for NC; for model, R
2 =
0.42, P , 0.0001) but was no longer sig-
niﬁcantwithBMIinthemodelrather than
VAT (P = 0.90 for NC). In sensitivity anal-
ysis using only women, NC remained sig-
niﬁcantly associated with cIMT. In the
subset for which physical activity was
available, adding activity to the model
did not change the signiﬁcance of NC in
relationship to cIMT (P = 0.02).
Inaseparateanalysisamongnon-HIV
control subjects, NC was signiﬁcantly
associated with cIMT, controlling for
traditional risk factors, including age,
sex, race, smoking, hypertension, glu-
cose, and lipids (P = 0.005 for NC; for
model, R
2 = 0.45, P , 0.0001, Table 4)
and in a model controlling for traditional
risk factors and VAT (P = 0.005 for NC;
Table 1—Demographic and clinical characteristics of the study population
Parameter
Group
P value
Adjusted
P value* HIV-infected HIV-negative
N 174 154
Demographics
Age (years) 44 6 14 3 6 10 . 4 3
Sex (n [%]) 0.08
Male 43 (25) 26 (17)
Female 131 (75) 128 (83)
Race (n [%]) 0.12
Caucasian 89 (51) 92 (60)
Non-Caucasian 85 (49) 62 (40)
Current smoking (n [%]) 90 (52) 40 (26) ,0.0001
Lifetime smoking (pack-years) 12.1 6 1.0 4.6 6 1.1 ,0.0001
Diabetes (n [%])† 9( 6 ) 3( 2 ) 0 . 1 0
HIV parameters
Duration HIV (months) 121 6 5N / A
CD4 (n/mm
3) 510 6 21 N/A
HIV viral load (copies/mL) 6,075 6 1,320 N/A
Duration PI use (months) 30 6 3N / A
Duration NRTI use (months) 59 6 4N / A
Duration NNRTI use (months) 16 6 2N / A
Metabolic parameters
Blood pressure (mmHg)
Systolic 116 6 11 1 4 6 1 0.24 0.43
Diastolic 74 6 17 2 6 1 0.05 0.12
Fasting glucose (mg/dL) 87 6 18 4 6 1 0.04 0.07
2-h glucose (mg/dL) 128 6 41 0 8 6 3 ,0.0001 ,0.0001
Fasting insulin (mU/mL) 8.9 6 0.7 5.7 6 0.3 0.0002 ,0.0001
Cholesterol (mg/dL)
Total 183 6 31 7 6 6 3 0.12 0.07
LDL 109 6 31 0 5 6 3 0.32 0.27
HDL 46 6 15 6 6 1 ,0.0001 ,0.0001
Triglycerides (mg/dL) 149 6 11 79 6 3 ,0.0001 ,0.0001
Average cIMT (mm) 0.68 6 0.01 0.66 6 0.01 0.26 0.48
Body composition parameters
BMI (kg/m
2) 26.6 6 0.4 27.5 6 0.4 0.11 0.10
WHR 0.93 6 0.01 0.86 6 0.01 ,0.0001 ,0.0001
SAT area (cm
2) 251 6 10 284 6 11 0.02 0.04
VAT area (cm
2)1 0 9 6 58 7 6 5 0.001 0.004
Arm fat by DEXA (kg) 2.6 6 0.1 3.0 6 0.1 0.005 0.01
Trunk fat by DEXA (kg) 11.6 6 0.4 11.6 6 0.4 0.91 0.94
Iliac waist (cm) 94 6 1.0 91 6 1.1 0.09 0.15
NC (cm) 37.0 6 0.3 36.4 6 0.3 0.50 0.80
Arm circumference (cm) 31.0 6 0.4 32.1 6 0.3 0.03 0.008
Data are reported as means 6 SEM or percentage. N/A, not applicable. *P value for effect of HIV infection
controlling for sex. †Diabetes diagnosed by 2-h OGTT, fasting blood glucose $126, and/or 2-h blood
glucose $200.
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2 = 0.45, P , 0.0001). In
contrast,intheanalysisoftheHIV-infected
cohort, NC was not a signiﬁcant predictor
of cIMT in models controlling for tradi-
tional risk factors with or without the ad-
dition of VAT (Table 4). Similar results
were seen when cumulative exposure to
PI, NRTI, and NNRTI was included in
the modeling (data not shown). Neither
CD4
+ count nor viral load was signiﬁ-
cantly associated with cIMT (data not
shown).
CONCLUSIONS—Although the asso-
ciation between visceral obesity and car-
diometabolic abnormalities is well
established (2), less is known about the
metabolic relevance of other upper body
subcutaneous fat stores. Upper body adi-
pose tissue is an important contributor to
circulating free fatty acids (FFA) and is
more lipolytically active than lower body
adipose tissue (15). Because FFA con-
centrationsaredirectlyassociatedwithin-
sulin resistance (16), hepatic VLDL
production (17), and endothelial dys-
function (18), upper body adipose tissue
may have important cardiovascular
and metabolic consequences (19). NC,
as a surrogate measure of upper body
adiposity, has been associated with nu-
merous cardiovascular risk factors in the
general population (20,21). Moreover, a
recent analysis of the Framingham Heart
Study demonstrated that NC is associated
with insulin resistance, elevated BP, and
dyslipidemia, independent of visceral
adiposity (9).
An important and novel aspect of the
current study is the signiﬁcant relation-
ship observed between NC and cIMT.
Our data extend the observations of the
Framingham Heart Study (9) by demon-
strating thatNC isassociatedwithadirect
measure of subclinical atherosclerosis,
cIMT, in the general population. To our
knowledge, this is the ﬁrst study to assess
the relationship between NC and cIMT.
The relationship between NC and cIMT
was independent of traditional risk fac-
tors, including smoking, hypertension,
LDL, glucose, and visceral adiposity.
The signiﬁcant independent relationship
between cIMT and NC seen among all
subjects held in a multivariate regression
analysis limited to HIV-negative patients.
However, the relationship did not remain
signiﬁcant when controlling for BMI in-
stead of VAT, which may be the result
of signiﬁcant covariance of NC and BMI.
ThesedatasuggestthatNCmayindicatea
high-risk adipose depot in relationship to
atherosclerotic indexes.
In subanalysis of the HIV-infected
cohort alone, NC was not a signiﬁcant
predictor of cIMT after controlling for
traditionalriskfactors.Theriskfactorsfor
CVD in HIV infection are numerous and
include traditional factors as well as life-
style factors and inﬂammatory and im-
mune status as characterized by markers
such as D-dimer (22), monocyte chemo-
attractant protein (MCP)-1 (23), and
decreased CD4
+ count (24). The nontra-
ditional factors contributing to CVD in
this population may explain the lack of
association between cIMT and NC, in
contrast with the signiﬁcant relationship
seen in the HIV-negative group. More-
o v e r ,N Cm a yb eam o r es t a b l ef a td e p o t ,
less affected by exposure to chronic ARVs
than other fat depots; changes in these
other depots, such as VAT, might drive
cIMT changes to a greater degree in the
HIV population.
In HIV infection, an association be-
tween upper trunk fat and insulin resis-
tance has been described (8), but the
relationship between NC per se and met-
abolic variables has not been character-
ized. We now show that among both
HIV and non-HIV groups, NC is strongly
associated with cardiometabolic risk fac-
tors,includingHDLand fasting insulin.It
is noteworthy that NC remains strongly
and signiﬁcantly associated with these
risk factors in models controlling for
VAT or BMI, demonstrating the impor-
tance of upper body fat, distinct from vis-
ceral fat, as a contributor to dyslipidemia
and insulin resistance. The lipolytic activ-
ity of upper body fat may mediate this re-
lationship with lipid metabolism and
glucose homeostasis. Studies of regional
lipolysis have demonstrated that, in the
postabsorptive state, ~50% of circulating
FFA is from nonsplanchnic upper body
fat stores (15). Of note, arm circumfer-
ence did not demonstrate the same asso-
ciationswithlipidandglucoseparameters
as NC in our cohort (data not shown),
possibly because arm circumference may
be more reﬂective of lean mass as well as
adiposity.
Our study has limitations. First, NC
is a measure of both adipose and lean
tissue, thus not a direct measure of adi-
posity, although our data suggest that it
is a good surrogate measure of adiposity
and, in fact, much more signiﬁcantly
related to cIMT than other measures of
upper body adiposity. There is variability
Table 2—Univariate associations between cardiometabolic parameters and NC in
HIV- and non–HIV-infected individuals
Parameter
Entire cohort
Group
HIV-infected HIV-negative
r* Pr * Pr * P
Age (years) 0.22 ,0.0001 0.20 0.008 0.23 0.004
Blood pressure (mmHg)
Systolic 0.25 ,0.0001 0.16 0.04 0.37 ,0.0001
Diastolic 0.30 ,0.0001 0.23 0.002 0.38 ,0.0001
Cholesterol (mg/dL)
Total 20.001 0.98 0.002 0.98 20.02 0.84
LDL 0.10 0.09 0.07 0.38 0.13 0.11
HDL 20.35 ,0.0001 20.25 0.002 20.48 ,0.0001
Triglycerides (mg/dL) 0.13 0.02 0.10 0.18 0.30 0.0002
Hemoglobin A1c (%) 0.20 0.0004 0.16 0.04 0.28 0.0006
Fasting glucose (mg/dL) 0.27 ,0.0001 0.27 0.0004 0.27 0.0008
Fasting insulin (mU/mL) 0.21 0.0005 0.18 0.03 0.26 0.003
2-h glucose (mg/dL) 0.02 0.73 20.04 0.62 0.09 0.31
Iliac waist circumference (cm) 0.68 ,0.0001 0.67 ,0.0001 0.70 ,0.0001
WHR 0.51 ,0.0001 0.49 ,0.0001 0.60 ,0.0001
BMI (kg/m
2) 0.57 ,0.0001 0.58 ,0.0001 0.57 ,0.0001
SAT area (cm
2) 0.35 ,0.0001 0.36 ,0.0001 0.35 ,0.0001
VAT area (cm
2) 0.60 ,0.0001 0.53 ,0.0001 0.69 ,0.0001
Arm fat by DEXA (kg) 0.37 ,0.0001 0.41 ,0.0001 0.35 ,0.0001
Trunk fat by DEXA (kg) 0.53 ,0.0001 0.54 ,0.0001 0.52 ,0.0001
Smoking history (pack-years) 0.08 0.17 0.10 0.21 0.03 0.76
*r is Pearson correlation coefﬁcient.
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shown this to be small. There are limited
dataontheeffectsofracialdifferencesand
lifestyle factors on measurements of NC,
andfurther dataareneededinthisregard.
Inclusion of patients with known diabe-
tes might have enhanced our ability to
describe associations between body
composition and glucose parameters
across a broader disease spectrum. How-
ever, by excluding subjects with known
diabetes, we avoided recruiting subjects
in whom our ability to see a strong re-
lationship with NC might have been
confounded by a high prevalence of di-
abetes. A small number of subjects met
criteria for diabetes on glucose tolerance
testing, and these data were included in
the analysis. Further studies examining
these speciﬁc relationships in large pop-
ulations with diabetes are now needed.
NC may be a strong predictor of obstruc-
tive sleep apnea (25). We cannot exclude
the possibility that the metabolic conse-
quences of obstructive sleep apnea may
confound the relationship between NC
and metabolic parameters. Longitudinal
data relating change in NC to cardiovas-
cular risk will be useful. Finally, cIMT
may be more difﬁcult to measure in sub-
jects with increasing neck girth, but we
show similar variance in the measure of
cIMT across NC quartiles, suggesting that
our results were not affected in this way.
Overall, our data highlight the meta-
bolic importance of upper body adiposity,
as measured by NC, in both HIV-infected
and HIV-negative individuals. In particu-
lar, NC isa strong predictor of measures of
insulin resistance and HDL cholesterol,
and, in HIV-negative individuals, is also
signiﬁcantly associated with cIMT. These
data reinforce the notion that upper body
fat is particularly and uniquely linked to
metabolic abnormalities, independent of
other measures of abdominal adiposity
such as VAT.
Acknowledgments—This work was sup-
ported by the National Institutes of Health
(NIH) grants R01-DK-049302 and K24-DK-
064545 (to S.K.G.) and M01-RR-01066 and
1-UL1-RR-025758-01; Harvard Clinical and
Translational Science Center; and from the
National Center for Research Resources. NIH
funding was also provided through K23-DK-
089910-01 (to T.L.S.) and K23-NR-011833-01
(to S.E.L.).
No potential conﬂicts of interest relevant to
this article were reported.
K.V.F. researched data, performed the
analysis, and wrote the manuscript. T.L.S.
performed data analysis and wrote the manu-
script.S.E.L.researcheddata and reviewedthe
manuscript. A.M.R. researched and compiled
data and reviewed the manuscript. S.K.G.
obtained funding, reviewed data analysis, and
edited and reviewed the manuscript.
The authors thank the subjects who par-
ticipated in this study and the nursing and
bionutritionstaffof theMassachusettsGeneral
Hospital and Massachusetts Institute of Tech-
nology Clinical Research Centers for their ex-
cellent patient care.
References
1. Triant VA, Lee H, Hadigan C, Grinspoon
SK. Increased acute myocardial infarction
Table 3—Univariate associations between cardiometabolic parameters and cIMT in
HIV- and non–HIV-infected individuals
Parameter
Entire cohort
Group
HIV-infected HIV-negative
r* Pr * Pr * P
Age (years) 0.53 ,0.0001 0.57 ,0.0001 0.49 ,0.0001
Blood pressure (mmHg)
Systolic 0.35 ,0.0001 0.35 ,0.0001 0.33 ,0.0001
Diastolic 0.30 ,0.0001 0.25 0.0009 0.34 ,0.0001
Cholesterol (mg/dL)
Total 0.06 0.32 20.03 0.69 0.18 0.03
LDL 0.07 0.22 20.06 0.47 0.24 0.003
HDL 20.04 0.50 0.14 0.07 20.21 0.01
Triglycerides (mg/dL) 20.006 0.92 20.08 0.32 0.17 0.04
Hemoglobin A1c (%) 0.22 ,0.0001 0.22 0.004 0.26 0.0014
Fasting glucose (mg/dL) 0.20 0.0005 0.15 0.06 0.25 0.003
Fasting insulin (mU/mL) 0.03 0.63 0.004 0.96 0.01 0.88
2-h Glucose (mg/dL) 0.10 0.10 0.08 0.35 0.10 0.22
Iliac waist circumference (cm) 0.24 ,0.0001 0.19 0.01 0.30 0.0002
WHR 0.21 0.0001 0.09 0.26 0.34 ,0.0001
BMI (kg/m
2) 0.16 0.004 0.15 0.05 0.19 0.02
SAT area (cm
2) 0.10 0.07 0.05 0.48 0.17 0.03
VAT area (cm
2) 0.16 0.005 0.04 0.64 0.30 0.0001
Arm fat by DEXA (kg) 0.05 0.36 0.04 0.57 0.09 0.29
Trunk fat by DEXA (kg) 0.08 0.13 0.03 0.66 0.15 0.06
Smoking history (pack-years) 0.39 ,0.0001 0.39 ,0.0001 0.38 ,0.0001
NC (cm) 0.25 ,0.0001 0.21 0.006 0.31 0.0001
*r is Pearson correlation coefﬁcient.
Table 4—Multivariate modeling of the relationship of traditional risk factors and NC to
average cIMT
Parameter
Entire cohort
Group
HIV-infected HIV-negative
b-Estimate P value b-Estimate P value b-Estimate P value
Age 0.006 ,0.0001 0.008 ,0.0001 0.004 0.0002
Sex (male) 0.000 1.00 0.004 0.77 20.011 0.41
Race (Caucasian) 20.013 0.04 20.015 0.11 20.013 0.11
HIV (HIV negative) 0.008 0.20 N/A N/A N/A N/A
Smoking pack-years 0.002 ,0.0001 0.002 0.008 0.003 ,0.0001
Hypertension or
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LDL (mg/dL) 0.000 0.53 0.000 0.98 0.000 0.14
Fasting glucose (mg/dL) 0.000 0.74 0.000 1.00 0.000 0.69
NC (cm) 0.005 0.02 0.003 0.39 0.009 0.005
For entire cohort, R
2 =0 . 4 1a n dP , 0.0001. For HIV-infected group, R
2 = 0.41 and P , 0.0001. For HIV-
negative group, R
2 =0 . 4 5a n dP , 0.0001.
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